|
1
|
Mardiana S, John LB, Henderson MA, Slaney
CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson
PJ, Loi S, et al: A multifunctional role for adjuvant anti-4-1BB
therapy in augmenting antitumor response by chimeric antigen
receptor T cells. Cancer Res. 77:1296–1309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tian YY, Jia CM, Li Y, Wang Y, Jiang L and
Liu AC: Restoration of microRNA-373 suppresses growth of human
T-cell lymphoma cells by repressing CCND1. Eur Rev Med Pharmacol
Sci. 20:4435–4444. 2016.PubMed/NCBI
|
|
3
|
Broll K, Richter G, Pauly S, Hofstaedter F
and Schwarz H: CD137 expression in tumor vessel walls. High
correlation with malignant tumors. Am J Clin Pathol. 115:543–549.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fu ZX, Han JS, Liu F, Zhao ZL, Li DB, Shi
L, Dong JT, Zhou Y and Cai JH: The study on specific umbilical
blood Dc vaccine for Beige nude mice loaded human colorectal
carcinoma to induce antitumor immunity. Eur Rev Med Pharmacol Sci.
21:2364–2371. 2017.PubMed/NCBI
|
|
5
|
Long AH, Haso WM, Shern JF, Wanhainen KM,
Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara
VR, et al: 4-1BB costimulation ameliorates T cell exhaustion
induced by tonic signaling of chimeric antigen receptors. Nat Med.
21:581–590. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Curran MA, Geiger TL, Montalvo W, Kim M,
Reiner SL, Al-Shamkhani A, Sun JC and Allison JP: Systemic 4-1BB
activation induces a novel T cell phenotype driven by high
expression of eomesodermin. J Exp Med. 210:743–755. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Madireddi S, Eun SY, Lee SW, Nemčovičová
I, Mehta AK, Zajonc DM, Nishi N, Niki T, Hirashima M and Croft M:
Galectin-9 controls the therapeutic activity of 4-1BB-targeting
antibodies. J Exp Med. 211:1433–1448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eun SY, Lee SW, Xu Y and Croft M: 4-1BB
ligand signaling to T cells limits T cell activation. J Immunol.
194:134–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoffmann JM, Schmitt M, Ni M and Schmitt
A: Next-generation dendritic cell-based vaccines for leukemia
patients. Immunotherapy. 9:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Berretta M, Fisichella R, Borsatti E,
Lleshi A, Ioffredo S, Meneguzzo N, Canzonieri V, Di Grazia A,
Cannizzaro R, Tirelli U, et al: Feasibility of intraperitoneal
trastuzumab treatment in a patient with peritoneal carcinomatosis
from gastric cancer. Eur Rev Med Pharmacol Sci. 18:689–692.
2014.PubMed/NCBI
|
|
11
|
Lipson EJ and Drake CG: Ipilimumab: An
anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res.
17:6958–6962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schabowsky RH, Elpek KG, Madireddi S,
Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ,
Mittler RS and Shirwan H: A novel form of 4-1BBL has better
immunomodulatory activity than an agonistic anti-4-1BB Ab without
Ab-associated severe toxicity. Vaccine. 28:512–522. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niu L, Strahotin S, Hewes B, Zhang B,
Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, et al:
Cytokine-mediated disruption of lymphocyte trafficking,
hemopoiesis, and induction of lymphopenia, anemia, and
thrombocytopenia in anti-CD137-treated mice. J Immunol.
178:4194–4213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma RK, Yolcu ES, Srivastava AK and
Shirwan H: CD4+ T cells play a critical role in the
generation of primary and memory antitumor immune responses
elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.
PLoS One. 8:e731452013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Srivastava AK, Sharma RK, Yolcu ES, Ulker
V, MacLeod K, Dinc G and Shirwan H: Prime-boost vaccination with
SA-4-1BBL costimulatory molecule and survivin eradicates lung
carcinoma in CD8+ T and NK cell dependent manner. PLoS
One. 7:e484632012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharma RK, Srivastava AK, Yolcu ES,
MacLeod KJ, Schabowsky RH, Madireddi S and Shirwan H: SA-4-1BBL as
the immunomodulatory component of a HPV-16 E7 protein based vaccine
shows robust therapeutic efficacy in a mouse cervical cancer model.
Vaccine. 28:5794–5802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Melero I, Johnston JV, Shufford WW,
Mittler RS and Chen L: NK1.1 cells express 4-1BB (CDw137)
costimulatory molecule and are required for tumor immunity elicited
by anti-4-1BB monoclonal antibodies. Cell Immunol. 190:167–172.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Navabi S, Doroudchi M, Tashnizi AH and
Habibagahi M: Natural killer cell functional activity after 4-1BB
costimulation. Inflammation. 38:1181–1190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Futagawa T, Akiba H, Kodama T, Takeda K,
Hosoda Y, Yagita H and Okumura K: Expression and function of 4-1BB
and 4-1BB ligand on murine dendritic cells. Int Immunol.
14:275–286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharma RK, Schabowsky RH, Srivastava AK,
Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ,
Yolcu ES, et al: 4-1BB ligand as an effective multifunctional
immunomodulator and antigen delivery vehicle for the development of
therapeutic cancer vaccines. Cancer Res. 70:3945–3954. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Srivastava AK, Dinc G, Sharma RK, Yolcu
ES, Zhao H and Shirwan H: SA-4-1BBL and monophosphoryl lipid A
constitute an efficacious combination adjuvant for cancer vaccines.
Cancer Res. 74:6441–6451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elpek KG, Yolcu ES, Franke DD, Lacelle C,
Schabowsky RH and Shirwan H: Ex vivo expansion of
CD4+CD25+FoxP3+ T regulatory cells
based on synergy between IL-2 and 4-1BB signaling. J Immunol.
179:7295–7304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Madireddi S, Schabowsky RH, Srivastava AK,
Sharma RK, Yolcu ES and Shirwan H: SA-4-1BBL costimulation inhibits
conversion of conventional CD4+ T cells into
CD4+ FoxP3+ T regulatory cells by production
of IFN-γ. PLoS One. 7:e424592012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma RK, Elpek KG, Yolcu ES, Schabowsky
RH, Zhao H, Bandura-Morgan L and Shirwan H: Costimulation as a
platform for the development of vaccines: A peptide-based vaccine
containing a novel form of 4-1BB ligand eradicates established
tumors. Cancer Res. 69:4319–4326. 2009. View Article : Google Scholar : PubMed/NCBI
|
